Sanofi said it will pay MannKind as much as $925 million for the global rights to inhaled insulin Afrezza, just a couple months after the treatment received FDA approval. Afrezza is the world's only inhaled insulin, an alternative to injections for adults with diabetes. MannKind will receive an upfront payment of $150 million and milestone payments of up to $775 million, depending on the drug's commercial success. Sanofi and MannKind will share profits and losses on a global basis, with Sanofi retaining 65% and MannKind receiving 35%. Sanofi said the deal is the latest opportunity for the company to bring another insulin option to people with diabetes around the globe.

More from Video

Biotech and Broadway Come Together to Fight Cancer

Biotech and Broadway Come Together to Fight Cancer

Market Movers: September Grain Stocks Report

Market Movers: September Grain Stocks Report

We Asked Our Pros About the Longevity of the Bull Market

We Asked Our Pros About the Longevity of the Bull Market

Legendary Technician Gives Her View of the Current Market

Legendary Technician Gives Her View of the Current Market

Cannabis: Why It May End Up in Your Portfolio

Cannabis: Why It May End Up in Your Portfolio